Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeting PRMT5-Mediated DNA Repair Pathway in Extra-Nodal NK/T-Cell Lymphoma (ENKTL)

Youssef Youssef, Walter Hanel, Wing Chan, Fiona C. Brown, Claire Hinterschied, Jobeth Helmig-Mason, Neha Bhagwat, Kris Vaddi, Peggy A Scherle, Amin Noorani, Sr., Aharon G. Freud, Lapo Alinari, Christopher C. Oakes, Bethany L. Mundy-Bosse, Robert Baiocchi

Blood (2024) 144 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2024-201980

Published: 2024

Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Blood (2023) 142 (Supplement 1): 423.

https://doi.org/10.1182/blood-2023-185321

Published: 2023

Journal Articles

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Yin Yuan, Sarah T Diepstraten, Fiona C. Brown, Veronique Litalien, Andreas Strasser, Gemma L Kelly, Andrew W. Roberts, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2023-179698

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Is BCL-xL the Achilles' heel of AEL and AMKL?

Fiona C. Brown, Andrew H. Wei

Blood (2023) 141 (13): 1505–1506.

https://doi.org/10.1182/blood.2022019246

Published: 2023

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

Journal Articles

The AP-1/ETS Transcription Factor Network Regulates Stem Cell Quiescence and Chemotherapy Resistance in Acute Myeloid Leukemia

Sumiko Takao, Victor Morell, Fiona C. Brown, Richard Koche, Alex Kentsis

Blood (2022) 140 (Supplement 1): 8682–8683.

https://doi.org/10.1182/blood-2022-165325

Published: 2022

Journal Articles

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Blood (2021) 138 (Supplement 1): 267.

https://doi.org/10.1182/blood-2021-145424

Published: 2021

Journal Articles

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Blood (2021) 137 (20): 2721–2735.

https://doi.org/10.1182/blood.2020010167

Published: 2021

Includes: Supplemental data

Journal Articles

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136872

Published: 2020

Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei

Blood (2019) 134 (Supplement_1): 3930.

https://doi.org/10.1182/blood-2019-129564

Published: 2019

Journal Articles

Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia

Kavitha Ramaswamy, MD, Lauren Forbes, Fiona C Brown, PhD, Richard Koche, PhD, Tatyana Gindin, MDPhD, Gerard Minuesa, PhD, Michael G. Kharas, PhD, Andrei Krivtsov, PhD, Scott A. Armstrong, MD PhD, Eric Still, Elisa de Stanchina, PhD, Randi Isenhart, Guangwu Guo, Birgit Knoechel, MDPhD, Alex Kentsis, MD PhD

Blood (2016) 128 (22): 3945.

https://doi.org/10.1182/blood.V128.22.3945.3945

Published: 2016

Journal Articles

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

Fiona C Brown, PhD, Eric Still, Paolo Cifani, PhD, Casie Reed, Scott Ficarro, PhD, Jie He, PhD, Richard Koche, PhD, Patrick Bhola, PhD, Peter Romanienko, PhD, Willie Mark, PhD, Andrei V. Krivtsov, PhD, Anthony Letai, MD PhD, Nathanael Gray, PhD, Jarrod Marto, PhD, Scott A. Armstrong, MD PhD, Alex Kentsis, MD PhD

Blood (2016) 128 (22): 436.

https://doi.org/10.1182/blood.V128.22.436.436

Published: 2016

Journal Articles

Activation of the erythroid K-Cl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model

Fiona C. Brown, Ashlee J. Conway, Loretta Cerruti, Janelle E. Collinge, Catriona McLean, James S. Wiley, Ben T. Kile, Stephen M. Jane, David J. Curtis

Blood (2015) 126 (26): 2863–2870.

https://doi.org/10.1182/blood-2014-10-609362

Published: 2015

Includes: Supplemental data

Journal Articles

Heterozygous Mutation Of Dynamin 2 Expands The Pool Of IL-7 Responsive Leukemic Stem Cells In T-Cell Acute Lymphoblastic Leukemia

David J. Curtis, M.D., Ph.D., Fiona C. Brown, BSc, Michael Collett, BSc, Sarah E. Lucas, BSc, Jesslyn Saw, Phillip J. Robinson, PhD, Cedric Stevens Tremblay

Blood (2013) 122 (21): 613.

https://doi.org/10.1182/blood.V122.21.613.613

Published: 2013

Journal Articles

A Novel DNM2 Mutation Displaying Embryonic Lethality and Impaired Transferrin Uptake Identified in a Mouse ENU Mutagenesis Screen for Genes Perturbing Erythropoiesis

Fiona C Brown, BSc, Michael Collett, BSc, Phillip J Robinson, PhD, James C Whisstock, PhD, Douglas J. Hilton, Benjamin T. Kile, Stephen M Jane, FRACP, FRCPA, MBBS, PhD, David J. Curtis, M.D., Ph.D.

Blood (2012) 120 (21): 608.

https://doi.org/10.1182/blood.V120.21.608.608

Published: 2012

NARROW

Targeting PRMT5-Mediated DNA Repair Pathway in Extra-Nodal NK/T-Cell Lymphoma (ENKTL)

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Is BCL-xL the Achilles' heel of AEL and AMKL?

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

The AP-1/ETS Transcription Factor Network Regulates Stem Cell Quiescence and Chemotherapy Resistance in Acute Myeloid Leukemia

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

Activation of the erythroid K-Cl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model

Heterozygous Mutation Of Dynamin 2 Expands The Pool Of IL-7 Responsive Leukemic Stem Cells In T-Cell Acute Lymphoblastic Leukemia

A Novel DNM2 Mutation Displaying Embryonic Lethality and Impaired Transferrin Uptake Identified in a Mouse ENU Mutagenesis Screen for Genes Perturbing Erythropoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only